Alteire

No Bias

[Alteire @Eagletrade5]

@Oculustrade $hims

[Alteire @Eagletrade5]

@himshouse Is he short $hims?

[Drug Money Capital ™️ @TheDrugMoney]

Buying $HIMS one month before peptides potentially move to category 1 is like owning the only fireworks factory in Philadelphia on July 3rd 1776 knowing exactly what was getting signed tomorrow.

[Alteire @Eagletrade5]

@alc2022 Next, $Hims at 100!

[Alteire @Eagletrade5]

@mvcinvesting Well diserved

[Alteire @Eagletrade5]

@himshouse @grok explain pls

[Alteire @Eagletrade5]

@mvcinvesting The stock is a real steal at these valuations with this growth rates

[Alteire @Eagletrade5]

@ZaStocks Yes relative strength. Ready to pop

[Alteire @Eagletrade5]

@WealthyReadings @mvcinvesting thoughts?

[Alteire @Eagletrade5]

@alc2022 What’s your take on $hims earnings?! Any worries about slowing growth? Evading GLP1 questions on the call? What future drivers besides peptides and international expansion are you seeing that shadows the risks now

[Alteire @Eagletrade5]

@Mr_Derivatives Double down

[Alteire @Eagletrade5]

@grok @CMDarnton0 @himshouse @gkroub @BaysideGrowth @grok Hims stopped selling the GLP1 pill, but not the inyectables, that means Novo was suing for the pill or the whole thing. Based on personalized threatments, how well protected is Hims?

[Alteire @Eagletrade5]

@CMDarnton0 @himshouse @gkroub @BaysideGrowth @grok explain preliminary injunction, and why would novo do it or why are they missing not doing it

[Alteire @Eagletrade5]

@himshouse @AndrewDudum @AndrewDudum you need to speak to the community. It’s been a wild ride since you twitched with a short squeeze post. Now 75% down from ATH, with NVO suing, FDA and DOJ allegations, it’s time to step up, be a confident leader and reassure the companies goals.

[Alteire @Eagletrade5]

@himshouse @himshouse contact @AndrewDudum for an emergency pod to speak to the retail community who has been loyal to the company. Now is a time to address what’s happening, what to expect from the management and the company and to calm the nerves.

[Alteire @Eagletrade5]

@AndrewDudum @grok give me a resume of the comments, are they positive, negative? Do they support Hims and Andrew?

[Alteire @Eagletrade5]

@NighthawkTradez @alc2022 It’ll be hilarious to have a Main Street $hims short squeeze. That’ll be a great middle finger to regulators, and big pharma, who’ve had been talking advantage and squeezing peoples pockets for decades. At 40% short interest. $hims squeeze, epic

[Alteire @Eagletrade5]

The $hims situation shows how big pharma is still in control of regulators by lobbying/interests. We haven’t seen a disruptor like $hims that isn’t afraid to confront and watch for people’s interests. #squeezeHIMS short squeeze them all, that’ll be a lesson.

[Alteire @Eagletrade5]

@US_FDA @grok this claims of non approved compounded drugs refer the the new pills released yesterday, or the inyectable glp1 too?

[Alteire @Eagletrade5]

@martypartymusic This liquidations are getting insane. Lots of leverage wiped , the rebound should be as epic